Diabetes Mellitus

On this page

DM Basics - Sweet Definitions

  • WHO Diagnostic Criteria (Any ONE):
    • Fasting Plasma Glucose (FPG): $\geq$ 126 mg/dL (7.0 mmol/L)
    • 2-hr Plasma Glucose (PG): $\geq$ 200 mg/dL (11.1 mmol/L) during OGTT (75g anhydrous glucose)
    • HbA1c: $\geq$ 6.5% (48 mmol/mol)
    • Random Plasma Glucose: $\geq$ 200 mg/dL (11.1 mmol/L) + symptoms of hyperglycemia
  • Types:
    • Type 1 DM (T1DM): Autoimmune $\beta$-cell destruction
    • Type 2 DM (T2DM): Insulin resistance & relative deficiency
    • Gestational DM (GDM): Diagnosed in 2nd/3rd trimester
    • LADA (Latent Autoimmune Diabetes in Adults)
    • MODY (Maturity-Onset Diabetes of the Young)
  • Epidemiology (India): High prevalence, often undiagnosed. Second largest number of DM patients globally.

⭐ HbA1c reflects average plasma glucose over the preceding 8-12 weeks (lifespan of RBCs).

Sugar Breakdown - Pathophysiology Unpacked

  • Type 1 DM (T1DM): Immune-mediated destruction of pancreatic β-cells, leading to absolute insulin deficiency.
    • Genetic predisposition (e.g., HLA-DR3, HLA-DR4).
    • Environmental triggers (e.g., viruses, toxins) initiate autoimmunity.
  • Type 2 DM (T2DM): Characterized by a combination of:
    • Insulin Resistance: Decreased peripheral tissue (muscle, fat) and hepatic response to insulin.
    • β-cell Dysfunction: Progressive decline in insulin secretion, often with amyloid deposition in islets. Results in relative insulin deficiency.

⭐ Glucotoxicity and lipotoxicity contribute to progressive β-cell dysfunction in T2DM, worsening hyperglycemia.

Spotting Sugar - Signs & Tests

  • Symptoms: 📌 Peeing (Polyuria), Parched (Polydipsia), Peckish (Polyphagia); weight loss (T1DM), fatigue, blurred vision, recurrent infections. Acanthosis nigricans (insulin resistance).
  • Diagnosis (ADA/WHO criteria - any ONE):
    • FPG $\ge$ 126 mg/dL
    • 2-hr PG (75g OGTT) $\ge$ 200 mg/dL
    • HbA1c $\ge$ 6.5%
    • RPG $\ge$ 200 mg/dL + symptoms
  • GDM Screening (24-28 wks):
    • IADPSG (75g OGTT): F $\ge$ 92, 1hr $\ge$ 180, 2hr $\ge$ 153 mg/dL (any 1 needed).

⭐ DIPSI (India specific): Single 75g OGTT (any time), 2-hr PG $\ge$ 140 mg/dL is diagnostic.

Taming the Sugar - Treatment Toolkit

  • Pillars: Lifestyle (diet, exercise) + Pharmacotherapy.
  • Initial Rx: Metformin (↓Hepatic glucose output; GI SEs).
  • Key OHAs:
    • Sulfonylureas (Glimepiride): ↑Insulin secretion. Risk: Hypoglycemia, Wt gain.
    • DPP-4 inhibitors (Sitagliptin): ↑Incretin levels. Weight neutral.
    • SGLT2 inhibitors (Dapagliflozin, Empagliflozin): ↑Renal glucose excretion. CV & Renal benefits. 📌 "Flozin for flow out"
  • Injectables:
    • GLP-1 RAs (Liraglutide, Semaglutide): ↑Incretin, Wt loss. CV benefits.
    • Insulin: Types (Rapid, Short, Intermediate, Long). Regimens (Basal, Basal-Bolus).
  • Targets: HbA1c generally <7%. Individualize (<6.5% young/new, <8% elderly/comorbid).

⭐ SGLT2 inhibitors (e.g., Empagliflozin, Canagliflozin, Dapagliflozin) reduce MACE and progression of diabetic kidney disease.

SGLT2 Inhibitor Mechanisms and Benefits

Sugar's Sting - Complications Galore

  • Acute: Diabetic Ketoacidosis (DKA), Hyperosmolar Hyperglycemic State (HHS) - emergencies.
  • Chronic Microvascular:
    • Retinopathy: Non-proliferative (NPDR), Proliferative (PDR); major cause of blindness.
    • Nephropathy: Microalbuminuria (Urine Albumin-Creatinine Ratio 30-300 mg/g) → End-Stage Renal Disease (ESRD).
    • Neuropathy: Peripheral (glove & stocking sensory loss), autonomic (gastroparesis, postural hypotension).
  • Chronic Macrovascular: Accelerated atherosclerosis - Coronary Artery Disease (CAD), Cerebrovascular Disease (CVD), Peripheral Vascular Disease (PVD).
  • Diabetic Foot: Ulcers, infections, Charcot arthropathy; risk of amputation. Diabetes Complications Chart

⭐ Microalbuminuria (UACR 30-300 mg/g) is the earliest detectable stage of diabetic nephropathy and a key screening target.

High‑Yield Points - ⚡ Biggest Takeaways

  • HbA1c ≥6.5% or FPG ≥126 mg/dL diagnoses Diabetes Mellitus.
  • Metformin: first-line oral agent for Type 2 DM; inhibits hepatic gluconeogenesis.
  • DKA: hyperglycemia, ketosis, anion gap metabolic acidosis; treat with IV fluids, insulin.
  • HHS: severe hyperglycemia, hyperosmolality, dehydration; minimal ketosis.
  • Diabetic retinopathy screening: at diagnosis for T2DM; 5 years post-diagnosis for T1DM.
  • ACE inhibitors/ARBs: preferred for hypertension in diabetics; renoprotective with microalbuminuria.
  • Dawn phenomenon vs. Somogyi effect: check 3 AM blood glucose to differentiate.

Practice Questions: Diabetes Mellitus

Test your understanding with these related questions

Among the following, most reliable test for screening of diabetes mellitus?

1 of 5

Flashcards: Diabetes Mellitus

1/10

_____ is a pancreatic islet cell tumor with a classic presentation of the 4 D s : diabetes, dermatitis, _____, and depression

TAP TO REVEAL ANSWER

_____ is a pancreatic islet cell tumor with a classic presentation of the 4 D s : diabetes, dermatitis, _____, and depression

Glucagonoma; deep vein thrombosis (DVT)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial